AMRI (AMRI) Hires VP Of International Sales

ALBANY, N.Y., March 5, 2015 /PRNewswire/ -- AMRI (NASDAQ: AMRI) announced today that Michael Pettersson, fills the newly created position of VP of International Sales, effective immediately. He reports to Christopher Conway, Senior Vice President of Global Sales and Marketing.

In this role, Mr. Pettersson will lead the international sales team in an effort to increase worldwide customer value and maximize market share in targeted market segments. Mr. Pettersson will drive strategy for sales and marketing efforts across AMRI's full ranges of services and products in Drug Discovery, Small Scale Development, API and Drug Products.

"We are pleased to welcome Michael to AMRI," said Mr. Conway. "As a sales and marketing professional with experience leading international sales activities across various territories worldwide, we are confident that he brings the international commercial expertise that will enhance AMRI's ability to improve the customer experience on a global basis.

Mr. Pettersson brings more than 30 years of international and commercial sales experience. Most recently he served as Senior Vice President at Teva API with worldwide sales responsibility. Mr. Pettersson holds an MBA in Marketing and Strategy from the Copenhagen Business School.

About AMRI
Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), and Drug Product Manufacturing. Our DDS segment provides comprehensive services from hit identification to IND, including expertise with diverse chemistry, library design and synthesis, in vitro biology and pharmacology, drug metabolism and pharmacokinetics, as well as natural products. API Manufacturing supports the chemical development and cGMP manufacture of complex API, including potent, controlled substances, biologics, peptides, steroids, and cytotoxic compounds. Drug Product Manufacturing supports drug product development through commercial scale production of complex liquid-filled and lyophilized parenteral formulations. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/amri-hires-vp-of-international-sales-300045696.html

SOURCE AMRI

Suggested Articles

The action will see Kiadis switch its attention to earlier-stage natural killer cell therapies against solid tumors and hematological cancers.

The Weill Family Foundation is stumping up $106 million to create a so-called “Neurohub.”

The takeover centers on TRPML1 agonists designed to treat neurodegenerative disorders by clearing toxic proteins from the brain.